miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors.

Florian Huemer; Michael Leisch; Roland Geisberger; Nadja Zaborsky; Richard Greil

doi:10.3390/ph14020089

miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors.

Florian Huemer (Erstautor/-in)
, Michael Leisch (Co-Autor/-in)
, Roland Geisberger (Co-Autor/-in)
, Nadja Zaborsky (Co-Autor/-in)
, Richard Greil^* (Letztautor/-in)

^*Korrespondierende/r Autor/-in für diese Arbeit

Universitätsklinik für Innere Medizin 3 - Hämatologie, internistische Onkologie, Hämostaseologie, Infektiologie, Rheumatologie und Onkologisches Zentrum

Publikation: Beitrag in Fachzeitschrift › Übersichtsarbeit › Begutachtung

14 Quellenangaben (Web of Science)

Originalsprache	Englisch
Fachzeitschrift	Pharmaceuticals (Basel, Switzerland)
Jahrgang	14
Ausgabenummer	2
DOIs	https://doi.org/10.3390/ph14020089
Publikationsstatus	Veröffentlicht - 2021

Zugriff auf Dokument

10.3390/ph14020089

Dieses zitieren

@article{d656f197fe774ef99ad157d98f95d588,

title = "miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors.",

keywords = "SQUAMOUS-CELL CARCINOMA, TUMOR-SUPPRESSOR MICRORNAS, LUNG-CANCER, OPEN-LABEL, SOLID TUMORS, DOUBLE-BLIND, NIVOLUMAB, PEMBROLIZUMAB, CHEMOTHERAPY, IPILIMUMAB",

author = "Florian Huemer and Michael Leisch and Roland Geisberger and Nadja Zaborsky and Richard Greil",

note = "all: Paracelsus Med Univ, Oncol Ctr, Dept Internal Med Haematol Med Oncol Haemostaseol, A-5020 Salzburg, Austria; ",

year = "2021",

doi = "10.3390/ph14020089",

language = "English",

volume = "14",

journal = "Pharmaceuticals (Basel, Switzerland)",

issn = "1424-8247",

publisher = "MDPI",

number = "2",

}

TY - JOUR

T1 - miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors.

AU - Huemer, Florian

AU - Leisch, Michael

AU - Geisberger, Roland

AU - Zaborsky, Nadja

AU - Greil, Richard

N1 - all: Paracelsus Med Univ, Oncol Ctr, Dept Internal Med Haematol Med Oncol Haemostaseol, A-5020 Salzburg, Austria;

PY - 2021

Y1 - 2021

KW - SQUAMOUS-CELL CARCINOMA

KW - TUMOR-SUPPRESSOR MICRORNAS

KW - LUNG-CANCER

KW - OPEN-LABEL

KW - SOLID TUMORS

KW - DOUBLE-BLIND

KW - NIVOLUMAB

KW - PEMBROLIZUMAB

KW - CHEMOTHERAPY

KW - IPILIMUMAB

U2 - 10.3390/ph14020089

DO - 10.3390/ph14020089

M3 - Review article

C2 - 33530393

SN - 1424-8247

VL - 14

JO - Pharmaceuticals (Basel, Switzerland)

JF - Pharmaceuticals (Basel, Switzerland)

IS - 2

ER -